Avenue Therapeutics Inc. (ATXI)
1.91
0.03 (1.60%)
At close: Jan 15, 2025, 12:16 PM
undefined% (undefined)
| Bid | 1.89 |
| Market Cap | 3.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 24.78 |
| PE Ratio (ttm) | 0.08 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.93 |
| Volume | 5,041 |
| Avg. Volume (20D) | 56,198 |
| Open | 1.89 |
| Previous Close | 1.88 |
| Day's Range | 1.89 - 1.94 |
| 52-Week Range | 1.60 - 15.00 |
| Beta | undefined |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York....
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 3
Stock Exchange NASDAQ
Ticker Symbol ATXI
Website https://www.avenuetx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ATXI stock is "Buy." The 12-month stock price forecast is $56.25, which is an increase of 2845.03% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
8 months ago ·
Source
-27.26%
Avenue Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
8 months ago ·
Source
-29.65%
Avenue Therapeutics shares are trading lower after the company announced a reverse stock split.
